Serina Therapeutics signs deal for up to USD 25 million unregistered common stock sales to Roth Principal Investments
SERA•Use of proceeds and term
Proceeds are earmarked for working capital and general corporate purposes.
The agreement runs for up to 36 months from commencement.
Issuance limits and pricing terms
Issuance cap set at 5,077,554 shares, or 19.99% of outstanding stock, unless shareholder approval is obtained or pricing meets a USD 2.77 base price.
Roth ownership is limited to 4.99% of outstanding shares; pricing is set at a discount to VWAP, with no upper limit on price.
Common stock purchase agreement with Roth Principal Investments
Serina Therapeutics signed a common stock purchase agreement with Roth Principal Investments for up to USD 25 million of newly issued common stock.
Shares may be issued in unregistered sales under Securities Act Section 4(a)(2) and Rule 506(b), subject to conditions including an effective resale registration statement.
